These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34045478)

  • 1. In silico analysis of BRCA1 and BRCA2 missense variants and the relevance in molecular genetic testing.
    Poon KS
    Sci Rep; 2021 May; 11(1):11114. PubMed ID: 34045478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics.
    Ernst C; Hahnen E; Engel C; Nothnagel M; Weber J; Schmutzler RK; Hauke J
    BMC Med Genomics; 2018 Mar; 11(1):35. PubMed ID: 29580235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/2 missense mutations and the value of in-silico analyses.
    Sadowski CE; Kohlstedt D; Meisel C; Keller K; Becker K; Mackenroth L; Rump A; Schröck E; Wimberger P; Kast K
    Eur J Med Genet; 2017 Nov; 60(11):572-577. PubMed ID: 28807866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.
    Hart SN; Hoskin T; Shimelis H; Moore RM; Feng B; Thomas A; Lindor NM; Polley EC; Goldgar DE; Iversen E; Monteiro ANA; Suman VJ; Couch FJ
    Genet Med; 2019 Jan; 21(1):71-80. PubMed ID: 29884841
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Stella S; Vitale SR; Massimino M; Martorana F; Tornabene I; Tomarchio C; Drago M; Pavone G; Gorgone C; Barone C; Bianca S; Manzella L
    Genes (Basel); 2024 Jul; 15(7):. PubMed ID: 39062721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.
    Tram E; Savas S; Ozcelik H
    PLoS One; 2013; 8(5):e62468. PubMed ID: 23704879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots".
    Dines JN; Shirts BH; Slavin TP; Walsh T; King MC; Fowler DM; Pritchard CC
    Genet Med; 2020 May; 22(5):825-830. PubMed ID: 31911673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico, in vitro and case-control analyses as an effective combination for analyzing BRCA1 and BRCA2 unclassified variants in a population-based sample.
    Rodríguez-Balada M; Roig B; Martorell L; Melé M; Salvat M; Vilella E; Borràs J; Gumà J
    Cancer Genet; 2016 Nov; 209(11):487-492. PubMed ID: 27886673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
    Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
    J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.
    Kim JH; Park S; Park HS; Park JS; Lee ST; Kim SW; Lee JW; Lee MH; Park SK; Noh WC; Choi DH; Han W; Jung SH
    Sci Rep; 2021 Apr; 11(1):8485. PubMed ID: 33875706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
    Parsons MT; Tudini E; Li H; Hahnen E; Wappenschmidt B; Feliubadaló L; Aalfs CM; Agata S; Aittomäki K; Alducci E; Alonso-Cerezo MC; Arnold N; Auber B; Austin R; Azzollini J; Balmaña J; Barbieri E; Bartram CR; Blanco A; Blümcke B; Bonache S; Bonanni B; Borg Å; Bortesi B; Brunet J; Bruzzone C; Bucksch K; Cagnoli G; Caldés T; Caliebe A; Caligo MA; Calvello M; Capone GL; Caputo SM; Carnevali I; Carrasco E; Caux-Moncoutier V; Cavalli P; Cini G; Clarke EM; Concolino P; Cops EJ; Cortesi L; Couch FJ; Darder E; de la Hoya M; Dean M; Debatin I; Del Valle J; Delnatte C; Derive N; Diez O; Ditsch N; Domchek SM; Dutrannoy V; Eccles DM; Ehrencrona H; Enders U; Evans DG; Farra C; Faust U; Felbor U; Feroce I; Fine M; Foulkes WD; Galvao HCR; Gambino G; Gehrig A; Gensini F; Gerdes AM; Germani A; Giesecke J; Gismondi V; Gómez C; Gómez Garcia EB; González S; Grau E; Grill S; Gross E; Guerrieri-Gonzaga A; Guillaud-Bataille M; Gutiérrez-Enríquez S; Haaf T; Hackmann K; Hansen TVO; Harris M; Hauke J; Heinrich T; Hellebrand H; Herold KN; Honisch E; Horvath J; Houdayer C; Hübbel V; Iglesias S; Izquierdo A; James PA; Janssen LAM; Jeschke U; Kaulfuß S; Keupp K; Kiechle M; Kölbl A; Krieger S; Kruse TA; Kvist A; Lalloo F; Larsen M; Lattimore VL; Lautrup C; Ledig S; Leinert E; Lewis AL; Lim J; Loeffler M; López-Fernández A; Lucci-Cordisco E; Maass N; Manoukian S; Marabelli M; Matricardi L; Meindl A; Michelli RD; Moghadasi S; Moles-Fernández A; Montagna M; Montalban G; Monteiro AN; Montes E; Mori L; Moserle L; Müller CR; Mundhenke C; Naldi N; Nathanson KL; Navarro M; Nevanlinna H; Nichols CB; Niederacher D; Nielsen HR; Ong KR; Pachter N; Palmero EI; Papi L; Pedersen IS; Peissel B; Perez-Segura P; Pfeifer K; Pineda M; Pohl-Rescigno E; Poplawski NK; Porfirio B; Quante AS; Ramser J; Reis RM; Revillion F; Rhiem K; Riboli B; Ritter J; Rivera D; Rofes P; Rump A; Salinas M; Sánchez de Abajo AM; Schmidt G; Schoenwiese U; Seggewiß J; Solanes A; Steinemann D; Stiller M; Stoppa-Lyonnet D; Sullivan KJ; Susman R; Sutter C; Tavtigian SV; Teo SH; Teulé A; Thomassen M; Tibiletti MG; Tischkowitz M; Tognazzo S; Toland AE; Tornero E; Törngren T; Torres-Esquius S; Toss A; Trainer AH; Tucker KM; van Asperen CJ; van Mackelenbergh MT; Varesco L; Vargas-Parra G; Varon R; Vega A; Velasco Á; Vesper AS; Viel A; Vreeswijk MPG; Wagner SA; Waha A; Walker LC; Walters RJ; Wang-Gohrke S; Weber BHF; Weichert W; Wieland K; Wiesmüller L; Witzel I; Wöckel A; Woodward ER; Zachariae S; Zampiga V; Zeder-Göß C; ; Lázaro C; De Nicolo A; Radice P; Engel C; Schmutzler RK; Goldgar DE; Spurdle AB
    Hum Mutat; 2019 Sep; 40(9):1557-1578. PubMed ID: 31131967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CoDP: predicting the impact of unclassified genetic variants in MSH6 by the combination of different properties of the protein.
    Terui H; Akagi K; Kawame H; Yura K
    J Biomed Sci; 2013 Apr; 20(1):25. PubMed ID: 23621914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2.
    Aljarf R; Shen M; Pires DEV; Ascher DB
    Sci Rep; 2022 Jun; 12(1):10458. PubMed ID: 35729312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1- and BRCA2-specific in silico tools for variant interpretation in the CAGI 5 ENIGMA challenge.
    Padilla N; Moles-Fernández A; Riera C; Montalban G; Özkan S; Ootes L; Bonache S; Díez O; Gutiérrez-Enríquez S; de la Cruz X
    Hum Mutat; 2019 Sep; 40(9):1593-1611. PubMed ID: 31112341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
    Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
    Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reclassification of
    Ha HI; Ryu JS; Shim H; Kong SY; Lim MC
    J Gynecol Oncol; 2020 Nov; 31(6):e83. PubMed ID: 33078592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations.
    Flanagan SE; Patch AM; Ellard S
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):533-7. PubMed ID: 20642364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a New, Endophenotype-Based Strategy for Pathogenicity Prediction in BRCA1 and BRCA2: In Silico Modeling of the Outcome of HDR/SGE Assays for Missense Variants.
    Özkan S; Padilla N; de la Cruz X
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variants of uncertain significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling.
    Moghadasi S; Hofland N; Wouts JN; Hogervorst FB; Wijnen JT; Vreeswijk MP; van Asperen CJ
    J Med Genet; 2013 Feb; 50(2):74-9. PubMed ID: 23231788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.